Fate Therapeutics (FATE) Amortization of Deferred Charges (2014 - 2019)
Fate Therapeutics (FATE) posted Amortization of Deferred Charges of $68000.0 for Q4 2019, up 353.33% on a QoQ basis from $15000.0 in Q3 2019, and up 257.89% year-over-year from $19000.0 in Q4 2018.
Fate Therapeutics (FATE) Amortization of Deferred Charges (2014 - 2019) Analysis & Trends
Fate Therapeutics' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $68000.0 for Q4 2019.
- Quarterly Amortization of Deferred Charges rose 257.89% year-over-year to $68000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $115000.0 (up 51.32% YoY) and the FY2019 annual result came in at $115000.0, up 51.32% from the prior year.
- Amortization of Deferred Charges was $68000.0 for Q4 2019 at Fate Therapeutics, up from $15000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $68000.0 in Q4 2019 and bottomed at $15000.0 in Q1 2019.
- A 5-year average of $29350.0 and a median of $21500.0 in 2017 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2015 — Amortization of Deferred Charges surged 1400.0% — and 2017, when it plunged 50.0%.
- Fate Therapeutics' Amortization of Deferred Charges stood at $44000.0 in 2015, then tumbled by 36.36% to $28000.0 in 2016, then slumped by 32.14% to $19000.0 in 2017, then changed by 0.0% to $19000.0 in 2018, then soared by 257.89% to $68000.0 in 2019.
- Business Quant data shows FATE's Amortization of Deferred Charges at $68000.0 in Q4 2019, $15000.0 in Q3 2019, and $17000.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Fate Therapeutics | 302.48 Mn | 302.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 68,000.00 |
| Dec 31, 2019 | 68,000.00 |
| Sep 30, 2019 | 15,000.00 |
| Sep 30, 2019 | 15,000.00 |
| Jun 30, 2019 | 17,000.00 |
| Jun 30, 2019 | 17,000.00 |
| Mar 31, 2019 | 15,000.00 |
| Mar 31, 2019 | 15,000.00 |
| Dec 31, 2018 | 19,000.00 |
| Dec 31, 2018 | 19,000.00 |
| Sep 30, 2018 | 19,000.00 |
| Sep 30, 2018 | 19,000.00 |
| Jun 30, 2018 | 19,000.00 |
| Jun 30, 2018 | 19,000.00 |
| Mar 31, 2018 | 19,000.00 |
| Mar 31, 2018 | 19,000.00 |
| Dec 31, 2017 | 19,000.00 |
| Dec 31, 2017 | 19,000.00 |
| Sep 30, 2017 | 19,000.00 |
| Sep 30, 2017 | 19,000.00 |